Dr Andreas Grabrucker writes :
In our research, we generate model systems to understand
neurobiological processes of brain development and function. Once the
pathomechanisms of brain diseases are identified, we aim to
develop targeted interventions, i.e., using Nanotechnology. In past
projects, we worked on the role of the bio-metal zinc as
an environmental factor implicated in Alzheimer’s Disease
and used the insights gained from our model systems for the
development of innovative drug-delivery systems.
Our
latest chapter, just published in the Elsevier book "Protein Homeostasis
Diseases", discusses how zinc binding to amyloid β and tau influences
aggregation and therapeutic opportunities.
Also, in another chapter, just published in the Elsevier book "Advances and Avenues
in the Development of Novel Carriers for Bioactives and Biological
Agents", discusses how novel nano carriers may open
new therapeutic opportunities.
No comments:
Post a Comment